CAS 625095-60-5

pradefovir

Description:

Pradefovir is an antiviral compound primarily investigated for its potential use in the treatment of hepatitis B virus (HBV) infections. It belongs to the class of nucleoside analogs, which function by mimicking the natural nucleotides that are essential for viral replication. The chemical structure of pradefovir includes a modified nucleoside backbone, which enhances its efficacy against HBV while minimizing resistance. It exhibits a favorable pharmacokinetic profile, allowing for effective oral bioavailability. Pradefovir is characterized by its ability to inhibit viral DNA polymerase, thereby disrupting the replication cycle of the virus. Additionally, it has shown a relatively low toxicity profile in preclinical studies, making it a candidate for further clinical evaluation. As with many antiviral agents, the development of pradefovir involves careful consideration of its therapeutic window, potential side effects, and interactions with other medications. Ongoing research aims to establish its long-term efficacy and safety in diverse patient populations.

Formula: C₁₇H₁₉ClN₅O₄P

Synonyms:

• ICN-20013
• CS-2902
• MB-06866
• Pradefovir (Remofovir)
• 9-[2-[[(2R,4S)-4-(3-Chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]ethyl]-9H-purin-6-amine
• 9H-Purin-6-amine, 9-[2-[[(2R,4S)-4-(3-chlorophenyl)-2-oxido-1,3,2-dioxaphosphorinan-2-yl]methoxy]ethyl]-
• (2R,4S)-2-{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}-4-(3-chlorophenyl)-1,3,2λ?-dioxaphosphinan-2-one
• MB06866,pradefovir
• Remofovir
• Diuron Impurity1
• ICN-2001-3
• pradefovir

Pradefovir

CAS: 625095-60-5

Pradefovir

Purity: ≥95%

Molecular weight: 423.79g/mol

Ref: 54-BUP00257

Pradefovir

Controlled Product

CAS: 625095-60-5

Applications Pradefovir is a prodrug that targets Adefovir (A247500) to liver for the treatment of hepatitis B.
References Reddy, K., et al.: J. Med. Chem., 51, 666 (2008);

Formula: C₁₇H₁₉ClN₅O₄P

Color and Shape: Neat

Molecular weight: 423.791

Ref: TR-P699405

Pradefovir

CAS: 625095-60-5

Pradefovir is a hydroxyl prodrug that is converted to its active form, Pradofloxacin, by esterases in the liver. Pradofloxacin has been shown to be effective against hiv and hepatitis C virus infections. This drug also has anti-inflammatory properties and inhibits the expression of toll-like receptor 4 (TLR4), which plays a role in HIV infection. Pradofloxacin has been approved for use as an oral prodrug for the treatment of hepatic steatosis. It is not known whether or not Pradofloxacin has any effect on TLR2 or TLR9 receptors.

Formula: C₁₇H₁₉ClN₅O₄P

Purity: Min. 95%

Molecular weight: 423.8 g/mol

Ref: 3D-AAB09560

Pradefovir

CAS: 625095-60-5

Pradefovir (Remofovir) is a prodrug for chronic HBV, converting to PMEA in the liver with a Km of 60 μM and clearance of 359 ml/min.

Formula: C₁₇H₁₉ClN₅O₄P

Purity: 97.50%

Color and Shape: Solid

Molecular weight: 423.79

Ref: TM-T28449